FINAL ANALYSIS OF GLOBAL SURVIVAL OF THE FIRST TEST IN PATIENTS WITH MULTIPLE NEW DIAGNOSTIC MYELOMA

被引：0

作者：

Oriol, A. ^{[1
]}

Facon, T. ^{[2
]}

Dimopoulos, M. ^{[3
]}

Dispenzieri, A. ^{[4
]}

Cavo, M. ^{[5
]}

Weisel, K. ^{[6
]}

Ludwig, H. ^{[7
]}

Delforge, M. ^{[8
]}

Geraldes, C. ^{[9
]}

Lee, J. J. ^{[10
]}

Chen, C. ^{[11
]}

De La Rubia, J. ^{[12
]}

White, D. ^{[13
]}

Binder, D. ^{[14
]}

Lu, J. ^{[15
]}

Kenneth, Anderson C. ^{[16
]}

Moreau, P. ^{[17
]}

Attal, M. ^{[18
]}

Fermand, J. P. ^{[19
]}

Loiseau, Avet H. ^{[20
]}

Haynes, Ervin A. ^{[21
]}

Chen, G. ^{[21
]}

Houck, V ^{[21
]}

Hulin, C. ^{[22
]}

Benboubker, L. ^{[23
]}

机构：

[1] Hosp Badalona Germans Trias & Pujol, ICO, Inst Josep Carreras, Badalona, Spain

[2] Hop Claude Huriez, Serv Malad Sang, Lille, France

[3] Univ Athens, Sch Med, Atenas, Greece

[4] Mayo Clin, Rochester, MN USA

[5] Bologna Univ, Sch Med, Seragnoli Inst Hematol, Bologna, Italy

[6] Univ Tubingen, Tubingen, Germany

[7] Wilhelminenspital Stadt Wien, Wilhelminen Canc Res Inst, Dept Med, Ctr Oncol Hematol & Palliat Care, Viena, Austria

[8] UZ Leuven, Dept Hematol, Leuven, Belgium

[9] Hosp Univ Coimbra, Coimbra, Portugal

[10] Chonnam Natl Univ, Hwasun Hosp, Dept Hematol Oncol, Hwasun Gun, Jeollanamdo, South Korea

[11] Princess Margaret Canc Ctr, Toronto, ON, Canada

[12] Hosp Univ & Politecn La Fe, Valencia, Spain

[13] Dalhousie Univ, QEII Hlth Sci Ctr, Halifax, NS, Canada

[14] Kantonsspital Winterthur, Winterthur, Switzerland

[15] Peking Univ, Peoples Hosp, Inst Hematol, Beijing, Peoples R China

[16] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA

[17] Univ Nantes, Nantes, France

[18] Inst Univ Canc Toulouse Oncopole, Toulouse, France

[19] Hop St Louis, Paris, France

[20] CHU Rangueil, Unite Genom Myelome, Toulouse, France

[21] Celgene Corp, Summit, NJ USA

[22] Bordeaux Hosp Univ Ctr CHU, Bordeaux, France

[23] CHU Tours, Hop Bretonneau, Tours, France

来源：

HAEMATOLOGICA | 2017年 / 102卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

CO-015

引用

页码：15 / 16

页数：2

共 50 条

[21] Aspirin Use and Survival in Multiple Myeloma Patients
Marinac, Catherine R.
Colditz, Graham A.
Rosner, Bernard
Ghobrial, Irene M.
Birmann, Brenda M.
BLOOD, 2018, 132
[22] Chemotherapy increases survival in patients with multiple myeloma
Nature Clinical Practice Oncology, 2008, 5 (1): : 9 - 9
[23] Socioeconomic Factors and Survival of Multiple Myeloma Patients
Chamoun, Kamal
Firoozmand, Amin
Caimi, Paolo
Fu, Pingfu
Cao, Shufen
Otegbeye, Folashade
Metheny, Leland
Patel, Seema
Gerson, Stanton L.
Boughan, Kirsten
De Lima, Marcos
Malek, Ehsan
CANCERS, 2021, 13 (04) : 1 - 12
[24] Comorbidities Influence Survival in Patients with Multiple Myeloma
Wildes, Tanya
Vij, Ravi
Colditz, Graham A.
BLOOD, 2011, 118 (21) : 1357 - 1358
[25] Bone Marrow Fibrosis In Patients With Multiple Myeloma: A New Prognostic Factor For Survival?
Hallgrimsdottir, Tinna
Porwit, Anna
Bjoerkholm, Magnus
Rossmann, Eva
Steingrimsdottir, Hlif
Lund, Sigrun Helga
Kristinsson, Sigurdur Y.
BLOOD, 2013, 122 (21)
[26] Peripheral blood myeloma cells as a prognostic factor for survival in patients with new, untreated multiple myeloma.
Witzig, TE
Gertz, MA
Lust, JA
Kyle, RA
OFallon, WM
Greipp, PR
BLOOD, 1995, 86 (10) : 217 - 217
[27] Marital Status and Survival in Patients with Multiple Myeloma: The Role of Marriage in the Management of Multiple Myeloma
Islam, Serajul
Lee, Chansoon
Kim, Jichan
Enright, Robert
Kotoucek, Pavel
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E259 - E260
[28] Calculated haemorheological profile and laboratory parameters in new diagnosed multiple myeloma patients: retrospective analysis according to survival
Carlisi, Melania
Lo Presti, Rosalia
Spoto, Corinne
Mancuso, Salvatrice
Siragusa, Sergio
Caimi, Gregorio
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2024, 15
[29] Impact of Socioeconomic Factors on Timeliness of First Line Chemotherapy and Survival in Patients with Active Multiple Myeloma
Jayakrishnan, Thejus
Bakalov, Veli
Wegner, Rodney E.
Sadashiv, Santhosh
BLOOD, 2019, 134
[30] ELOQUENT-3 study: elotuzumab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma - final analysis of overall survival (OS)
Raab, M. S.
Dimopoulos, M.
Dytfeld, D.
Grosicki, S.
Moreau, P.
Takezako, N.
Hori, M.
Leleu, X.
LeBlanc, R.
Suzuki, K.
Richardson, P. G.
Popa McKiver, M.
Jou, Y. -M.
Yao, D.
Das, P.
San-Miguel, J.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 87 - 87

← 1 2 3 4 5 →